A real-world snapshot of where your biomarker stands today
NeoGenomics Biomarker Briefs deliver concise, publication-ready prevalence and testing trend analyses, scoped to a single biomarker and tumor type, drawn directly from our clinicogenomic database. The fastest way to get defensible, lab-confirmed biomarker intelligence without commissioning a full data study.
CommercializationPre-launch landscape intelligence
Understand the current testing landscape before your therapy reaches the market. Know where testing volume is highest, where concordance gaps exist, and what the eligible population actually looks like in practice.
- Territory and account-level testing volume data
- Concordance benchmarks to frame field education objectives
- Trend data showing trajectory heading into launch
Medical AffairsScientific briefings and publication support
A structured, citable biomarker prevalence analysis ready for internal scientific briefings, advisory boards, or as a data exhibit in a manuscript or abstract.
- Pre-formatted data exhibits ready for slide decks and manuscripts
- Cohort definitions and methodology fully documented
- Comparable across tumor types for multi-indication programs
Research | HEORPopulation sizing and payer evidence
Fast, defensible prevalence data for payer dossier sections, budget impact models, and burden-of-disease frameworks, without commissioning a full RWE study.
- Lab-confirmed positivity for biomarker-eligible population sizing
- Testing gap data for unmet-need framing
- Available as recurring updates to track market evolution
Clinical Trial OptimizationFeasibility and eligibility benchmarking
Validate biomarker prevalence assumptions before I/E criteria are locked. So you can understand whether the eligible population in the community setting matches what was assumed at protocol design.
- Real-world prevalence vs. literature-based assumptions
- Setting and region breakdown for site selection planning
- Modality-level data to inform CDx strategy discussions